indacaterol vs olodaterol
Side-by-side comparison of indacaterol and olodaterol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Arcapta Neohaler
Striverdi Respimat
No summary available.
Striverdi Respimat is a medicine that helps people with COPD breathe easier. It contains olodaterol, which is a long-acting beta-2 agonist (LABA).
Information not available.
Striverdi Respimat is used long-term to treat COPD, including chronic bronchitis and emphysema. It helps to open up the airways in your lungs, making it easier to breathe. This medicine is not for sudden COPD symptoms or for asthma.
Information not available.
Olodaterol is a LABA. It works by relaxing the muscles around your airways. This helps to open them up so air can flow in and out of your lungs more easily.
- • Common cold symptoms (nasopharyngitis)
- • High blood pressure (hypertension)
- • Common cold symptoms
- • Cough
- • Back pain
No adverse event reports.
No adverse event reports.
No specific warnings noted.
LABAs like olodaterol can raise the risk of asthma-related death if used alone to treat asthma. Striverdi Respimat is not for asthma. Using too much Striverdi Respimat can cause serious heart problems and may be fatal. If you have a bad reaction, like swelling or trouble breathing, stop using Striverdi Respimat and get medical help right away.
No pregnancy information available.
Tell your doctor if you are pregnant or plan to become pregnant. Striverdi Respimat should only be used during pregnancy if the benefit outweighs the risk to the baby. It is not known if Striverdi Respimat passes into breast milk.
Also Compare, Nearby Drugs
Compare indacaterol with
Compare olodaterol with
How to Read This indacaterol vs olodaterol Comparison
indacaterol is classified in the Long-Acting Beta-2 Agonist (LABA) drug class, while olodaterol sits within the Long-Acting Beta-2 Agonist (LABA) class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, indacaterol has 0 submissions while olodaterol has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between indacaterol and olodaterol - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.